CK-3773274 (5 - 15 mg) for Hypertrophy

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Oregon Health & Science University, Portland, OR
Hypertrophy+3 More
CK-3773274 (5 - 15 mg) - Drug
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a drug may be safe for long-term use.

See full description

Eligible Conditions

  • Hypertrophy
  • Symptomatic Hypertrophic Cardiomyopathy (HCM)

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether CK-3773274 (5 - 15 mg) will improve 2 primary outcomes and 6 secondary outcomes in patients with Hypertrophy. Measurement will happen over the course of Baseline through the end of participation at 12-week intervals.

Baseline through the end of participation at 12-week intervals
Long-term effects of CK-3773274 on left ventricular outflow tract gradient (LVOT G)
Long-term effects of CK-3773274 on left ventricular outflow tract gradient (LVOT G) in patients with oHCM
Year 5
Incidence of adverse events observed during dosing of CK-3773274 in patients with HCM
Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of CK-3773274 in patients with HCM
Incidence of serious adverse events observed during dosing of CK-3773274 in patients with HCM
Year 5
Incidence of adverse events observed during dosing of CK-3773274 in patients with oHCM
Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of CK-3773274 in patients with oHCM
Incidence of serious adverse events observed during dosing of CK-3773274 in patients with oHCM

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Trial Design

2 Treatment Groups

CK-3773274 up to 15 mg
1 of 2
CK-3773274 up to 20 mg
1 of 2
Experimental Treatment

This trial requires 300 total participants across 2 different treatment groups

This trial involves 2 different treatments. CK-3773274 (5 - 15 Mg) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

CK-3773274 up to 15 mg
Drug
Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
CK-3773274 up to 20 mg
Drug
Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: to end of study, up to 5 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly to end of study, up to 5 years for reporting.

Closest Location

Oregon Health & Science University - Portland, OR

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Completion of a Cytokinetics trial investigating CK-3773274
LVEF ≥55% at the Screening Visit

Patient Q&A Section

Is ck-3773274 (5 - 15 mg) typically used in combination with any other treatments?

"It is unlikely if not impossible to combine CK-3773274 with any treatments other than placebo. The only exception is if CK-3773274 is co-administered with amiodarone. Further clinical trials are required to verify this interaction." - Anonymous Online Contributor

Unverified Answer

What causes cardiomyopathy, hypertrophic?

"Cardiomyopathy, hypertrophic and dilated cardiomyopathy are all multifactorial diseases with the same main cause being genetic defects in the t-tubulin complex. There are no effective treatments to cure the condition. However, there are medications which can alleviate symptoms and prevent deterioration of heart function." - Anonymous Online Contributor

Unverified Answer

What is cardiomyopathy, hypertrophic?

"Cardiomyopathy, hypertrophic is a generalized heart muscle disease characterized by a myocardial hypertrophy with ventricular dilation. Clinically, cardiomyopathy, hypertrophic manifests in a variety of ways including unexplained shortness of breath with exercise; congestive heart failure; sudden death in young, fit individuals; and failure of the heart muscle to adequately support the body. Causes of cardiomyopathy, hypertrophic are varied but are often due to physical and/or chemical traumas. Some causes include certain medications, dietary supplements, toxins, and infections." - Anonymous Online Contributor

Unverified Answer

Can cardiomyopathy, hypertrophic be cured?

"The recovery of cardiac function was possible in 20% of those treated with TAC therapy and was accompanied by an important improvement in quality of life. However, in our study, mortality did not seem to be a prerequisite of cure although it was a strong negative predictor." - Anonymous Online Contributor

Unverified Answer

What are common treatments for cardiomyopathy, hypertrophic?

"Although rare, most cases of cardiomyopathy secondary to an ST-segment-elevation myocardial infarction can be managed with medication (for example ACE inhibitors, beta-blockers, and aldosterone antagonists) such as propranolol and atenolol and surgical revascularization. There is no known cure for cardiomyopathy, and thus, treatment is focused on symptomatic treatments of symptoms to minimize discomfort.\n" - Anonymous Online Contributor

Unverified Answer

What are the signs of cardiomyopathy, hypertrophic?

"There are a wide variety of symptoms that can occur with cardiomyopathy, often with multiple possible causes. A sudden onset of heart failure without any preceding illness often coincides with a viral infection and therefore warrants the use of a thorough family history. A wide variety of symptoms, some rare, can be brought on by fever. For these reasons, patients and their families should be aware that the first symptom may be fatigue with weight loss. Some signs and symptoms, like shortness of breath, may represent both symptoms of congestive heart failure and pulmonary edema.\nanswer: If you have any signs or symptoms that are suggestive of cardiomyopathy, call your doctor. Prompt evaluation could prevent death from any cause." - Anonymous Online Contributor

Unverified Answer

How many people get cardiomyopathy, hypertrophic a year in the United States?

"There are over 11 million patients being observed with cardiomyopathy, hypertrophic cardiomyopathy and cardiac hypertrophy in the United States each year. Approximately two thirds of people with cardiomyopathy, hypertension and hypertrophy have no other risk factors. Risk factors include male sex, smoking, family history, high blood pressure and lack of physical activity are associated with cardiac disease." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of ck-3773274 (5 - 15 mg)?

"The side effects of the study drug ck-3773274 did not warrant discontinuation. These side effects were generally mild or moderate. Fatigue, nausea, constipation, and sweating were the most commonly reported side effects. Most of these side effects typically occurred during the first 2 weeks of ck-3773274 treatment. There was no sign of drug-induced toxicity." - Anonymous Online Contributor

Unverified Answer

What is ck-3773274 (5 - 15 mg)?

"CK-3773274 is safer, more effective and orally bioavailable than adalimumab in this population of subjects with mild-to-moderate rheumatoid arthritis with cardiomyopathy. Results support the need for further evaluation of CK-3773274 as a potential treatment in patients with rheumatoid arthritis and cardiomyopathy." - Anonymous Online Contributor

Unverified Answer

What does ck-3773274 (5 - 15 mg) usually treat?

"Findings from a recent study demonstrates that ck-3773274, a 5-15 mg dose formulation, provides effective short-term (up to 2x the recommended number of injections) treatment of cardiomyopathy in a cohort of elderly patients that presented with worsening shortness of breath and a systolic heart murmur." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating cardiomyopathy, hypertrophic?

"In recent years, several therapeutic drugs and other technologies have been described but none of them are currently recommended for treating patients with cardiomyopathy, hypertrophic." - Anonymous Online Contributor

Unverified Answer

How serious can cardiomyopathy, hypertrophic be?

"[The cardiomyopathy, hypertrophic is serious because it causes symptoms that may get worse and may have a higher likelihood of death than can be had by other cardiomyopathy, hypertrophic subtypes.]"

"Oxycanus pseudopunctatus\n\nOxycanus pseudopunctatus is a moth of the family Hepialidae. It is found in New Guinea"

"Cerithium mariepompoi\n\nCerithium mariepompoi is a species of minute sea snail, a marine gastropod mollusk in the family Cerithiidae, the ceriths." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Hypertrophy by sharing your contact details with the study coordinator.